Cargando…

Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse

Background Maintenance therapy with 5-aminosalicylic acid (5-ASA) is a key strategy for preventing relapse in many patients with inflammatory bowel disease (IBD). Factors which disrupt 5–ASA delivery, such as non-adherence and 5-ASA switches, may destabilise symptom control. Aim To investigate the i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Robinson, A, Hankins, M, Wiseman, G, Jones, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley 2013
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840705/ https://www.ncbi.nlm.nih.gov/pubmed/23834298 http://dx.doi.org/10.1111/apt.12396

Ejemplares similares

Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease
por: Kiesslich, R, et al.
Publicado: (2011)

Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort
por: Gros, Beatriz, et al.
Publicado: (2023)

Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: the VERNE study
por: Marin-Jimenez, Ignacio, et al.
Publicado: (2020)

Uncoupling of mucosal gene regulation, mRNA splicing and adherent microbiota signatures in inflammatory bowel disease
por: Häsler, Robert, et al.
Publicado: (2017)

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
por: Panaccione, R, et al.
Publicado: (2013)

Relapse after withdrawal from anti‐TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta‐analysis
por: Kennedy, N. A., et al.
Publicado: (2016)

Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)
por: Carbery, Isabel, et al.
Publicado: (2023)

Colonic mucosa-associated diffusely adherent afaC+ Escherichia coli expressing lpfA and pks are increased in inflammatory bowel disease and colon cancer
por: Prorok-Hamon, Maelle, et al.
Publicado: (2014)

Changing paradigms in management of inflammatory bowel disease
por: Mao, Ren, et al.
Publicado: (2022)

Environmental risk factors for inflammatory bowel disease
por: Singh, Noreen, et al.
Publicado: (2022)

New endoscopic tools in inflammatory bowel disease
por: Nardone, Olga Maria, et al.
Publicado: (2022)

Ultrasonography in inflammatory bowel disease – So far we are?
por: Christian, Maaser, et al.
Publicado: (2022)

Landscape of new drugs and targets in inflammatory bowel disease
por: Vieujean, Sophie, et al.
Publicado: (2022)

Is hypertension an extra‐intestinal manifestation of inflammatory bowel disease?
por: Burisch, Johan
Publicado: (2023)

Avoiding food avoidance in patients with inflammatory bowel disease
por: Godny, Lihi, et al.
Publicado: (2023)

Faecal metabolome and its determinants in inflammatory bowel disease
por: Vich Vila, Arnau, et al.
Publicado: (2023)

Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease
por: Koelink, Pim J, et al.
Publicado: (2014)

Subclinical bowel inflammation increases healthcare resources utilization and steroid use before diagnosis of inflammatory bowel disease
por: Rodríguez‐Lago, Iago, et al.
Publicado: (2022)

Physical Fitness in Adolescence and Subsequent Inflammatory Bowel Disease Risk
por: Melinder, Carren, et al.
Publicado: (2015)

Endoscopy and histology in inflammatory bowel diseases patients: Complementary or alternatives?
por: D'Amico, Ferdinando, et al.
Publicado: (2022)

Identifying and understanding disease burden in patients with inflammatory bowel disease
por: Christensen, Katrine Risager, et al.
Publicado: (2022)

Inflammatory bowel disease cross‐sectional imaging: What's new?
por: Wang, Yang‐di, et al.
Publicado: (2022)

The role of gut microbiome in inflammatory bowel disease diagnosis and prognosis
por: Zheng, Jiaying, et al.
Publicado: (2022)

Smoking and colorectal cancer in inflammatory bowel disease: Quantity matters?
por: Marafini, Irene, et al.
Publicado: (2023)

Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease
por: Cayatte, Corinne, et al.
Publicado: (2012)

Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune‐mediated inflammatory diseases: A European retrospective observational study
por: Goessens, Laurent, et al.
Publicado: (2021)

Smoking and colorectal neoplasia in patients with inflammatory bowel disease: Dose‐effect relationship
por: Wijnands, Anouk M., et al.
Publicado: (2023)

The Inflammatory Bowel Diseases and Ambient Air Pollution: A Novel Association
por: Kaplan, Gilaad G, et al.
Publicado: (2010)

Outcomes of inflammatory bowel disease in patients with eosinophil-predominant colonic inflammation
por: Alhmoud, Tarik, et al.
Publicado: (2020)

Implications of the changing epidemiology of inflammatory bowel disease in a changing world
por: Agrawal, Manasi, et al.
Publicado: (2022)

The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries
por: Aniwan, Satimai, et al.
Publicado: (2022)

Body image dissatisfaction in patients with inflammatory bowel disease: a systematic review
por: Beese, Sophie Elizabeth, et al.
Publicado: (2019)

Assessment of patients' understanding of inflammatory bowel diseases: Development and validation of a questionnaire
por: Ostromohov, Gaiana, et al.
Publicado: (2021)

Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease
por: Grišić, Ana‐Marija, et al.
Publicado: (2021)

Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study
por: Clooney, Adam G, et al.
Publicado: (2021)

International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases
por: D'Amico, Ferdinando, et al.
Publicado: (2021)

Diversion proctocolitis and the problem of the forgotten rectum in inflammatory bowel diseases: A systematic review
por: Dal Buono, Arianna, et al.
Publicado: (2021)

Optimising inflammatory bowel disease surveillance and dysplasia management—Where do we stand?
por: Al Bakir, Ibrahim, et al.
Publicado: (2022)

Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases
por: Michaudel, Chloé, et al.
Publicado: (2023)

Polygenic risk score predicts risk of primary sclerosing cholangitis in inflammatory bowel disease
por: Wang, Ming-Hsi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gqg768g5i39tsdknto0b0rasfn